Co-Authors
This is a "connection" page, showing publications co-authored by JONATHAN LEI and MEENAKSHI ANURAG.
Connection Strength
2.058
-
LIG1 Loss in TP53-mutant Triple Negative Breast Cancer Rewires DNA Repair and Confers Sensitivity to PARP-ATR Inhibitor Combinations. Mol Cancer Ther. 2026 Jul 15.
Score: 0.247
-
Proteogenomic analysis of the CALGB 40601 (Alliance) HER2+ breast cancer neoadjuvant trial reveals resistance biomarkers. Cell Rep Med. 2025 Jun 17; 6(6):102154.
Score: 0.228
-
Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses. bioRxiv. 2025 Jan 08.
Score: 0.222
-
The Breast Cancer Proteome and Precision Oncology. Cold Spring Harb Perspect Med. 2023 10 03; 13(10).
Score: 0.203
-
Proteogenomic Markers of Chemotherapy Resistance and Response in Triple-Negative Breast Cancer. Cancer Discov. 2022 11 02; 12(11):2586-2605.
Score: 0.191
-
Endocrine therapy resistance: new insights. Breast. 2019 Nov; 48 Suppl 1:S26-S30.
Score: 0.155
-
Functional Annotation of ESR1 Gene Fusions in Estrogen Receptor-Positive Breast Cancer. Cell Rep. 2018 08 07; 24(6):1434-1444.e7.
Score: 0.142
-
NF1 loss in estrogen receptor-positive breast cancer induces osteoclast formation and immunosuppression to promote bone metastasis. Cancer Lett. 2026 Sep 01; 655:218636.
Score: 0.061
-
NF1-depleted ER+ breast cancers are differentially sensitive to CDK4/6 inhibitors. Sci Transl Med. 2025 08 27; 17(813):eadq5492.
Score: 0.058
-
Proteogenomic characterization unveils biomarkers associated with chemoresistance in muscle-invasive bladder cancer. Cell Rep Med. 2025 Aug 19; 6(8):102255.
Score: 0.058
-
PKMYT1 Is a Marker of Treatment Response and a Therapeutic Target for CDK4/6 Inhibitor-Resistance in ER+ Breast Cancer. Mol Cancer Ther. 2024 10 01; 23(10):1494-1510.
Score: 0.055
-
Kinome Reprogramming Is a Targetable Vulnerability in ESR1 Fusion-Driven Breast Cancer. Cancer Res. 2023 10 02; 83(19):3237-3251.
Score: 0.051
-
Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins. Cancer Res Commun. 2023 08; 3(8):1551-1563.
Score: 0.050
-
Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor-positive Breast Cancers for Targeted Treatment. Cancer Res Commun. 2023 07; 3(7):1366-1377.
Score: 0.050
-
Elevated NRAS expression during DCIS is a potential driver for progression to basal-like properties and local invasiveness. Breast Cancer Res. 2022 10 18; 24(1):68.
Score: 0.048
-
Transcriptional Reprogramming Differentiates Active from Inactive ESR1 Fusions in Endocrine Therapy-Refractory Metastatic Breast Cancer. Cancer Res. 2021 12 15; 81(24):6259-6272.
Score: 0.044
-
Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. Cancer Cell. 2021 03 08; 39(3):361-379.e16.
Score: 0.042
-
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy. Cell. 2020 11 25; 183(5):1436-1456.e31.
Score: 0.042
-
Neurofibromin Is an Estrogen Receptor-a Transcriptional Co-repressor in Breast Cancer. Cancer Cell. 2020 03 16; 37(3):387-402.e7.
Score: 0.040
-
Copy number alterations associated with clinical features in an underrepresented population with breast cancer. Mol Genet Genomic Med. 2019 07; 7(7):e00750.
Score: 0.038
-
Loss of MutL Disrupts CHK2-Dependent Cell-Cycle Control through CDK4/6 to Promote Intrinsic Endocrine Therapy Resistance in Primary Breast Cancer. Cancer Discov. 2017 10; 7(10):1168-1183.
Score: 0.033